文献速递炎症性肠病

综述:COVID-19大流行期间炎症性肠病患者的疫苗接种

Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic.
PubMed 文献 · Aliment Pharmacol Ther · 2021-09-02

该综述总结了炎症性肠病(IBD)患者接种现有疫苗后的免疫应答情况,发现使用免疫调节剂和抗TNF药物会降低应答率。建议IBD患者尽早接种COVID-19疫苗,接种前应处于缓解期并尽可能减少糖皮质激素剂量。

要点

  • IBD患者对疫苗的免疫应答低于一般人群。
  • 免疫调节剂和抗TNF药物会降低疫苗应答率。
  • 应尽早接种COVID-19疫苗,不应因免疫调节治疗而推迟。

核心结论

  • IBD患者应尽早接种COVID-19疫苗,接种前应处于缓解期并尽可能减少糖皮质激素剂量。

研究设计与样本

  • 本文为文献综述,总结了IBD患者接种目前推荐疫苗及COVID-19疫苗的免疫应答相关文献。

主要发现

  • IBD患者接种疫苗后的免疫应答低于一般人群。
  • 使用免疫调节剂和抗TNF药物会降低应答率。
  • 接受抗TNF治疗(尤其联合免疫调节剂)的患者在接种一剂COVID-19疫苗后抗体滴度可能降低。

临床怎么用

  • IBD患者应尽早接种COVID-19疫苗,不应因正在接受免疫调节治疗而推迟接种。
  • 接种前应优化可能影响疫苗应答的已有危险因素,使患者处于缓解期并尽可能减少糖皮质激素剂量。

局限性

  • 需进一步研究不同生物制剂对COVID-19疫苗应答的影响。
  • 需进一步研究IBD人群中加强针或异源初免-加强接种的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poor immune responses are frequently observed in patients with inflammatory bowel disease (IBD) receiving established vaccines; risk factors include immunosuppressants and active disease. AIMS: To summarise available information regarding immune responses achieved in patients with IBD receiving established vaccines. Using this information, to identify risk factors in the IBD population related to poor vaccine-induced immunity that may be applicable to vaccines against COVID-19. METHODS: We undertook a literature review on immunity to currently recommended vaccines for patients with IBD and to COVID-19 vaccines and summarised the relevant literature. RESULTS: Patients with IBD have reduced immune responses following vaccination compared to the general population. Factors including the use of immunomodulators and anti-TNF agents reduce response rates. Patients with IBD should be vaccinated against COVID-19 at the earliest opportunity as recommended by International Advisory Committees, and vaccination should not be deferred because a patient is receiving immune-modifying therapies. Antibody titres to COVID-19 vaccines appear to be reduced in patients receiving anti-TNF therapy, especially in combination with immunomodulators after one vaccination. Therefore, we should optimise any established risk factors that could impact response to vaccination in patients with IBD before vaccination. CONCLUSIONS: Ideally, patients with IBD should be vaccinated at the earliest opportunity against COVID-19. Patients should be in remission and, if possible, have their corticosteroid dose minimised before vaccination. Further research is required to determine the impact of different biologics on vaccine response to COVID-19 and the potential for booster vaccines or heterologous prime-boost vaccinations in the IBD population.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Doherty J, Fennessy S, Stack R, et al. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther. 2021. PMID: 34472643. doi:10.1111/apt.16590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。